Publication

Effective Visualizations Using “vachette” to Assess and Communicate Pharmacometric Model Results

Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…

CertaraOctober 15, 2025

Live Events

PKUK 2025 Pre-Conference Workshop: Modeling & Simulation Updates – QSP and PK/PD Software

– Scarman, Coventry, UK

CertaraOctober 14, 2025

Publication

Exploring the Population Pharmacokinetic and Pharmacogenetics Characteristics of Flurbiprofen Isomers in Selective Joint Replacement Patients with Postoperative Pain

Find out how Phoenix NLME identifies pharmacogenetic drivers of flurbiprofen enantiomer clearance and CSF distribution…

CertaraOctober 9, 2025

Blog

Alzheimer’s disease clinical trials and drug development: Building a robust clinical pharmacology & model-informed strategy

Rajesh Krishna proposes using an integrated clinical pharmacology & model-informed strategy for Alzheimer's disease clinical…

CertaraOctober 7, 2025

White Paper

C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions

Replace or waive TQT studies with validated C-QT analysis strategies accepted by FDA, EMA, PMDA.…

CertaraOctober 3, 2025

Case Study

Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer

Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…

CertaraOctober 2, 2025

Publication

Pharmacokinetics, Bioequivalence, and Safety of Bromocriptine Mesylate Tablets in Healthy Chinese Subjects

Explore how fed‑condition crossover study confirms bromocriptine mesylate bioequivalence and safety, analysed using Phoenix WinNonlin.

CertaraSeptember 29, 2025

Publication

Pharmacokinetics, Relative Bioavailability, and Safety of the SHR0302 Oral Solution and Tablets: A Single-Center, Randomized, Open-Label, Crossover (Two-Formulation, Two-Period) Phase I Trial in Healthy Chinese Volunteers

Discover how oral solution and tablet formulations of SHR0302 show comparable bioavailability and safety in…

CertaraSeptember 26, 2025

Conference

37th Annual Meeting of the Southern California Chapter Society of Toxicology (SCCSOT)

CertaraSeptember 22, 2025

On-Demand Webinar

Certara University: Introducing Certara’s Phoenix Cloud TFL Studio: Streamlined Creation of Tables, Figures & Listings

Watch Certara’s webinar with Kristin Follman to discover how TFL Studio streamlines the process to…

CertaraSeptember 22, 2025

Clinical Pharmacology

Effective Visualizations Using “vachette” to Assess and Communicate Pharmacometric Model Results

PKUK 2025 Pre-Conference Workshop: Modeling & Simulation Updates – QSP and PK/PD Software

Exploring the Population Pharmacokinetic and Pharmacogenetics Characteristics of Flurbiprofen Isomers in Selective Joint Replacement Patients with Postoperative Pain

Alzheimer’s disease clinical trials and drug development: Building a robust clinical pharmacology & model-informed strategy

C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions

Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer

Pharmacokinetics, Bioequivalence, and Safety of Bromocriptine Mesylate Tablets in Healthy Chinese Subjects

Pharmacokinetics, Relative Bioavailability, and Safety of the SHR0302 Oral Solution and Tablets: A Single-Center, Randomized, Open-Label, Crossover (Two-Formulation, Two-Period) Phase I Trial in Healthy Chinese Volunteers

37th Annual Meeting of the Southern California Chapter Society of Toxicology (SCCSOT)

Certara University: Introducing Certara’s Phoenix Cloud TFL Studio: Streamlined Creation of Tables, Figures & Listings

Newsletter sign up

Quick links

Solutions

Contact